Living in deprived areas of England doubles cervical cancer risk
Findings from a new study have prompted Mayo Clinic researchers to recommend CYP2D6 gene testing for postmenopausal women about to begin tamoxifen therapy. This data confirms that women with an inherited deficiency in the CYP2D6 gene, which is important for the metabolism of tamoxifen, have a nearly fourfold higher risk of early breast cancer recurrence
Full Post: Postmenopausal patients being considered for tamoxifen therapy should be tested for CYP2D6 gene deficiency
Women living in the most deprived areas of England are nearly twice as likely to be diagnosed with cervical cancer than their affluent counterparts - according to a report presented by national cancer director Professor Mike Richards at the Britain Against Cancer conference today (Tuesday).
The report, published by the National Cancer Intelligence Network (NCIN), reveals a ‘deprivation gap’ that researchers believe is mainly fuelled by a lower uptake of cervical screening in deprived areas.
All cases of cancer diagnosed between 1995 and 2004 were included in this nation-wide analysis of the effect of deprivation on cancer incidence, including more than 25,000 cases of cervical cancer.
In the most deprived areas of England, there were 12 women per 100,000 diagnosed with cervical cancer between 2000 and 2004. In the most affluent areas, only 6 per 100,000 women were diagnosed with the disease during the same time period.
Professor David Forman, NCIN information lead who is based at the University of Leeds, said: “These striking figures show there is still much more that needs to be done to tackle cancer in low-income communities.
“Cervical cancer is a largely preventable disease - the national screening programme will pick up most cases before they even develop into cancer. Our figures suggest that women living in poorer areas are less likely to attend cervical screening than women who are better-off, so they are more likely to develop the disease.
“Higher rates of smoking in most deprived areas and the earlier onset of sexual activity also contribute to the higher rates of cervical cancer.”
Currently, women in England aged 25 to 64 are invited for cervical screening every three to five years. In 2006, around 20 per cent of women in England invited for cervical screening did not attend, and previous research has shown that women in deprived areas are around 40 per cent less likely to attend. Screening can pick up on important changes to cells before cervical cancer develops.
Sara Hiom, director of health information at Cancer Research UK, said: “It’s extremely worrying that your income and where you live can have such a significant effect on your risk of cancer. It’s clear that much more needs to be done to encourage women from low-income communities to attend cervical screening.”
Women living in deprived areas were 129 per cent more likely to be diagnosed with cervical cancer between 1995 and 1999. This figure was 106 per cent between 2000 and 2004. Although this drop is not statistically significant, doctors hope this downwards turn will continue.
Professor Mike Richards, who will present the report on behalf of the NCIN, said: “Reducing inequalities in cancer incidence and uptake of cancer services is a key aim set out in the Cancer Reform Strategy. Collecting and understanding data like this is a crucial first step in achieving this goal. The NHS Cancer Screening Programme is working with the Improvement Foundation, to improve the uptake of cervical screening in poor areas through targeted pilot programmes. The lessons learnt from this work due in 2009, will be shared with Strategic Health Authorities and local screening programmes to develop best practice.”
Professor Julietta Patnick CBE, director of NHS Cancer Screening Programmes, said: “This is a helpful report shedding light on the relationship between cancer and deprivation. Over recent years we have seen a downward trend in women taking up their screening invitation, especially younger women and those in deprived inner city areas, and the reasons for this are difficult to determine. Cervical screening saves around 4,500 lives a year, and it is important for women to consider this when deciding whether or not to accept their invitation.”
Sara Hiom added: “Most cases of cervical cancer are caused by HPV - a sexually transmitted virus - and smoking increases the chances of the virus causing cancer. Greater awareness of the link with smoking and, most importantly, of cervical screening are all key to reducing the risk of cervical cancer in deprived areas. Cancer Research UK is investing in research to understand how to improve public health and cervical screening coverage in low-income groups.”
As a part of National Cervical Health Awareness Month, Acting Secretary of Health Everette James has reminded women of the importance of cervical cancer prevention and the need for pap tests. “Every January as we begin a new year, we want to remind all Pennsylvanians to do what they can to improve their overall health,”
Full Post: Women reminded yearly examinations best way to prevent cervical cancer
Just under five per cent of the men who took part in the prostate cancer element of the USA’s largest ever cancer screening trial were diagnosed with the disease and the majority of those were picked up by screening programmes, according to research published in the December issue of the UK-based urology journal BJU International.
Full Post: Prostate cancer screening programme shows high compliance and consistent results in more than 38,000 men
The use of human papillomavirus (HPV) DNA testing as an initial screening step followed by triage with a standard Pap test (cytology) and repeat HPV DNA testing may increase the accuracy of cervical cancer screening, according to a study in the Jan. 13 online issue of the Journal of the National Cancer Institute. Compared to
Full Post: HPV testing followed by cytology and repeat HPV testing may improve cervical cancer screening
BD Diagnostics, a segment of BD (Becton, Dickinson and Company) has announced that it received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for the BD FocalPoint(TM) GS Imaging System. This innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath(TM) Pap test slides to detect evidence
Full Post: BD Diagnostics receives FDA approval for imaging system that enhances detection of cervical cancer
Non-fatal self-harm may occur in over ten per cent of adults discharged from psychiatric inpatient care in England and Wales, according to new research from the University of Bristol published in the BMJ. The risk was found to be greatest in the first month, Professor David Gunnell and colleagues found. Patients who had previous self-harming
Full Post: Patients at risk of self-harm after discharge from psychiatric care